On August 22, 2024, Cascade Pharmaceuticals announced the official launch of a Phase I clinical trial for its THR-β agonist, CS060380.The trial, titled "A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of Single and Multiple Ascending Doses of CS060380 in Healthy Subjects and Participants with Elevated LDL-C", successfully held its kickoff meeting at Xuhui Central Hospital in Shanghai.
Recently, Cascade Pharmaceuticals announced that its independently developed Class I new drug, CS060304, has received implicit approval for clinical trial application (IND) from the U.S. Food and Drug Administration (FDA).About CS060304CS060304 is a small molecule agonist targeting thyroid receptor
Cascade recently announced thatthe new FXR agonist CS0159, jointly developed by the team of Eric Xu, founder of Shanghai Institute of Medicine, and Li Jia, team of Shanghai Institute of Medicine, is aimed at NASH-CS0159-002 carried out in the United States for non-alcoholic fatty liver disease
Recently, Cascade announced that the new FXR agonist CS0159 jointly developed by Eric Xu, the founder of the company, and Li Jia, the founder of the Shanghai Institute of Pharmacy, won the qualification of the Fast Track of the US Food and Drug Administration (FDA) for the treatment of patients with
Recently, Cascade announced that the new FXR agonist CS0159, jointly developed by Eric Xu, the founder of the company, and Li Jia, the team of the Shanghai Institute of Pharmacy, has obtained the implied permission of the US Food and Drug Administrat
沪ICP备88888888号
